tbuckley/cabot-search huggingface dataset:
AB0275 Differences in The Clinical Evaluation of Joints in Patients with Rheumatoid Arthritis and Secondary Sjögren Syndrome
Authors: K. Romanowska-Prόchnicka, M. Olesińska, A. Paradowska-Gorycka, A. Felis-Giemza, M. Mańczak, D. Szukiewicz
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Secondary Sjögren syndrome (sSS) is classified as a connective tissue disease characterized mainly by xerophthalmia and xerostomia, and accompanied by various autoimmune diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus, scleroderma, vasculitis, mixed connective tissue disease, primary biliary cirrhosis or autoimmune thyroiditis. <h3>Objectives</h3> To investigate whether a difference exists between DAS28 from CRP and DAS28 from ESR in patients with rheumatoid arthritis (RA) and secondary Sjögren syndrome (sSS). <h3>Methods</h3> The study included patients with rheumatoid arthritis (RA) and secondary Sjögren syndrome (sSS). The inclusion criteria have been specified as follows: radiological confirmation of rheumatoid arthritis, presence of data on DAS28-CRP and DAS28-OB, presence of at least one subjective and one objective symptom of dryness, and also presence of specific antibodies or at least focus score one in biopsy. <h3>Results</h3> Disease activity score 28 (DAS28) was assessed using both ESR and CRP in 60 patients with RA and sSS and 59 patients with RA alone. Although concordance between these two methods was good (Cohen9s kappa coefficient κ=0.60, 95% of CI (0.45–0.75) in first group and κ=0,71, 95% of CI (0.56–0.86) in control group). In the group with RA and sSS mean value of DAS28-ESR=5.2, whereas mean value of DAS28-CRP=4.7 (p&lt;0.0001). In the group with RA alone mean DAS-ESR=4,7 while mean DAS-CRP=4,6, no significant difference was identified. Moreover, in RA patients with sSS mean ESR=39mm/h compared with mean CRP at 25mg/dl. 79% of all patients demonstrated dysproteinemia. There were connections between higher ESR and dysproteinemia. In control group there were no significant difference between CRP and ESR. <h3>Conclusions</h3> Both DAS28-ESR and DAS28-CRP are useful outcome measures in RA. However, in patients with RA and sSS DAS28 should be evaluated based on CRP or SDAI. <h3>Disclosure of Interest</h3> None declared
A Humanized Anti-Ganglioside GM2 Antibody, BIW-8962, Exhibits ADCC/CDC Activity against Multiple Myeloma Cells and Potent Anti- Tumor Activity in Mouse Xenograft Models.
Authors: Toshihiko Ishii, Asher Alban Chanan-Khan, Jazur Jafferjee, Noreen Ersing, Takeshi Takahashi, Masato Mizutani, Yukimasa Shiotsu, Nobuo Hanai
Journal: Blood (2008)
Prevalence of functional tumors in neuroendocrine carcinoma: An analysis from the NCCN NET database.
Authors: Michael A. Choti, Sarah Bobiak, Jonathan R. Strosberg, Al Bowen Benson, Mark Bloomston, James C. Yao, Carrie C. Zornosa, Emily K. Bergsland, Matthew Kulke, Eric K. Nakakura, Manisha H. Shah
Journal: Journal of Clinical Oncology (2012)

4126 Background: Neuroendocrine tumors (NETs) are increasing in incidence and prevalence. Identification and treatment of specific clinical NET syndromes are established, yet there is uncertainty regarding the prevalence of NET with hormone-related symptoms versus nonfunctional tumors. Methods: The National Comprehensive Cancer Network (NCCN) created a comprehensive database to characterize patients (pts) treated for NETs. This database was queried to identify pts presenting to 7 NCCN institutions with a confirmed NET diagnosis: including carcinoid (cNET), pancreatic NET (pNET), NET not otherwise specified (NOS), and pheochromocytoma (PCC) between 2004 and 2010. The primary aim of this analysis was to describe demographic and clinical characteristics of NET pts by functional (fxn) status at diagnosis (dx). Results: Among 1244 NET pts, 26% (n=327) had an fxn tumor. Carcinoid syndrome (CS) occurred in 28% of cNET pts. The most common primary tumor sites among CS pts were small bowel (69%) and unknown (15%). Prevalence of hormonal syndrome (HS) among pNET pts was 22%, 24% among NOS pts and 37% among PCC pts. The majority of CS pts (74%), pNET HS pts (67%), and NOS HS pts (91%) had distant disease at dx, in contrast to 31% of PCC HS patients. Among CS pts with a known histologic grade, 91% were well differentiated (G1). Similarly, 86% of pNET HS and 67% of NOS HS pts with a known histologic grade had G1 NETs. The most common symptoms at dx among pts with CS included abdominal cramping (53%), change in bowel habits (48%), and flushing (40%). Among those tested, 85% of CS pts had a positive 5-HIAA test at dx. Among pNET HS pts, the most common symptoms present at dx were abdominal cramping (39%) and change in bowel habits (46%). The most common symptoms present at dx among NOS HS pts were abdominal cramping (35%), change in bowel habits (47%) and flushing (38%). Conclusions: Prevalence of CS in this NCCN database (28%) was slightly higher than the 10% previously reported in the literature. In contrast, the prevalence of HS among pNET pts (22%) was lower than previously reported. Approximately one quarter of cNET pts without metastatic disease had CS, warranting further analysis as CS most often occurs in the presence of liver metastasis.
Incidence and Risk Factors for Central Nervous System (CNS) Relapse In Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Analysis with Competing Risk Regression (CRR) Model
Authors: Dai Chihara, Yasuhiro Oki, Keitaro Matsuo, Hiroshi Onoda, Hirofumi Taji, Kazuhito Yamamoto, Yasuo Morishima
Journal: Blood (2010)
Ticagrelor, but not clopidogrel, reduces arterial thrombosis via endothelial tissue factor suppression
Authors: Martin F Reiner, Alexander Akhmedov, Simona Stivala, Stephan Keller, Daniel S Gaul, Nicole R Bonetti, Gianluigi Savarese, Martina Glanzmann, Cuicui Zhu, Wolfram Ruf, Zhihong Yang, Christian M Matter, Thomas F Lüscher, Giovanni G Camici, Juerg H Beer
Journal: Cardiovascular Research (2016)

The P2Y12 antagonist ticagrelor reduces mortality in patients with acute coronary syndrome (ACS), compared with clopidogrel, and the mechanisms underlying this effect are not clearly understood. Arterial thrombosis is the key event in ACS; however, direct vascular effects of either ticagrelor or clopidogrel with focus on arterial thrombosis and its key trigger tissue factor have not been previously investigated.Human aortic endothelial cells were treated with ticagrelor or clopidogrel active metabolite (CAM) and stimulated with tumour necrosis factor-alpha (TNF-α); effects on procoagulant tissue factor (TF) expression and activity, its counter-player TF pathway inhibitor (TFPI) and the underlying mechanisms were determined. Further, arterial thrombosis by photochemical injury of the common carotid artery, and TF expression in the murine endothelium were examined in C57BL/6 mice treated with ticagrelor or clopidogrel. Ticagrelor, but not CAM, reduced TNF-α-induced TF expression via proteasomal degradation and TF activity, independently of the P2Y12 receptor and the equilibrative nucleoside transporter 1 (ENT1), an additional target of ticagrelor. In C57BL/6 mice, ticagrelor prolonged time to arterial occlusion, compared with clopidogrel, despite comparable antiplatelet effects. In line with our in vitro results, ticagrelor, but not clopidogrel, reduced TF expression in the endothelium of murine arteries.Ticagrelor, unlike clopidogrel, exhibits endothelial-specific antithrombotic properties and blunts arterial thrombus formation. The additional antithrombotic properties displayed by ticagrelor may explain its greater efficacy in reducing thrombotic events in clinical trials. These findings may provide the basis for new indications for ticagrelor.
Serum Soluble LR11 Can Predict High FLIPI-2 Score in Follicular Lymphoma.
Authors: Takeharu Kawaguchi, Chikako Ohwada, Naomi Shimizu, Masahiro Takeuchi, Emiko Sakaida, Yusuke Takeda, Shio Sakai, Shokichi Tsukamoto, Atsuko Yamazaki, Morihiro Higashi, Jun-Ichi Tamaru, Kotaro Yokote, Hideaki Bujo, Chiaki Nakaseko
Journal: Blood (2012)
Collection of Peripheral Blood Stem Cells in 668 Patients with Multiple Myeloma Treated on Total Therapy II (UARK 98-026).
Authors: K. A. Hollmig, J. M. Stover, M. C. Fox, L. C. Jackson, G. Talamo, A. Fassas, M. Zangari, C. K. Lee, F. Van Rhee, E. Anaissie, G. Tricot, B. Barlogie
Journal: Blood (2004)
Quantitative Monitoring Of Wilms’ Tumor 1 Expression In Predicting Relapse After Allogeneic Hematopoietic Stem Cell Transplantation In Patients With Acute Leukemia and Myelodysplastic Syndrome
Authors: Ryotaro Nakamura, Anna Israyelyan, Leanne Goldstein, Weimin Tsai, Lia Aquino, Stephen J. Forman, Don Diamond
Journal: Blood (2013)
Maintenance Rituximab Every 2 Months for 2 Years Is Effective and Well Tolerated In Patients with Follicular Lymphoma with Both Standard or Rapid Infusion: Updated Results From the Phase IIIb MAXIMA Study
Authors: Robin Foá, Alice Di Rocco, Guy van Hazel, Dalton FA Chamone, Klaus Ruffert, Jacob M. Rowe, Luca Arcaini, Irina Poddubnaya, Anthony D. Ho, Valentina Ivanova, Andrej Vranovsky, Mathias Witzens-Harig
Journal: Blood (2010)
Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking
Authors: Joachim Weischenfeldt, Taronish Dubash, Alexandros P Drainas, Balca R Mardin, Yuanyuan Chen, Adrian M Stütz, Sebastian M Waszak, Graziella Bosco, Ann Rita Halvorsen, Benjamin Raeder, Theocharis Efthymiopoulos, Serap Erkek, Christine Siegl, Hermann Brenner, Odd Terje Brustugun, Sebastian M Dieter, Paul A Northcott, Iver Petersen, Stefan M Pfister, Martin Schneider, Steinar K Solberg, Erik Thunissen, Wilko Weichert, Thomas Zichner, Roman Thomas, Martin Peifer, Aslaug Helland, Claudia R Ball, Martin Jechlinger, Rocio Sotillo, Hanno Glimm, Jan O Korbel
Journal: Nature Genetics (2016)
Epigenetic Down-Regulation of NFkB-Mediated FAS Gene Transcription During Progression of Myelodysplastic Syndromes
Authors: Sandrine Ettou, Catherine Humbrech, Blandine Benet, Katy Billot, Virginie Mariot, Olivier Kosmider, Catherine Lacombe, Patrick Mayeux, Eric Solary, Michaela Fontenay
Journal: Blood (2012)
Conditioned Medium Originated From Lethally Irradiated Umbilical Cord Blood-Derived Mononuclear Cells Has Different Pro-Angiogenic Effects Over Mature and Progenitor Endothelial Cells In Vitro
Authors: Marila Cervio, Claudia Del Fante, Luigia Scudeller, Gianluca Viarengo, Cesare Perotti
Journal: Blood (2013)
Basophils Promote Tumor Rejection via Chemotaxis and Infiltration of CD8+ T Cells
Authors: Ibrahim M. Sektioglu, Rafael Carretero, Nadja Bulbuc, Tobias Bald, Thomas Tüting, Alexander Y. Rudensky, Günter J. Hämmerling
Journal: Cancer Research (2016)

Abstract Elevated numbers of regulatory T cells (Treg) in patient tumors are known to inhibit efficient antitumor T-cell responses. To study the mechanisms controlling tumor rejection, we assessed different mouse models for Treg depletion. In Foxp3DTR knock-in mice, about 99% Treg depletion was achieved, resulting in complete rejection of transplanted HCmel12 melanomas in a CD8+ T-cell–dependent way. In contrast, about 90% Treg depletion obtained in BAC transgenic Foxp3.LuciDTR4 mice failed to induce complete rejection of HCmel12 melanomas, demonstrating that residual Tregs were able to control CD8+ T-cell responses against the tumor. Ninety-nine percent of Treg depletion provoked drastic changes in the tumor microenvironment, such as strong infiltration of CD8+ T cells and basophils. Intratumoral basophils enhanced CD8+ T-cell infiltration via production of chemokines CCL3 and CCL4; antibody-based blocking of these chemokines inhibited CD8+ T-cell infiltration. Therapeutic induction of basophilia by IL3/anti-IL3 antibody complexes, combined with transfer of CD8+ T cells, resulted in enhanced T-cell infiltration and tumor rejection. Our study identifies a critical role basophils play in tumor rejection and that this role can be exploited for therapeutic intervention. Cancer Res; 77(2); 291–302. ©2016 AACR.
Assessing the Intracellular Integrity of Phosphine-Stabilized Ultrasmall Cytotoxic Gold Nanoparticles Enabled by Fluorescence Labeling
Authors: Janine Broda, Andrea Küster, Stefan Westhues, Dirk Fahrenkamp, Andreas T. J. Vogg, Julia Steitz, Felix M. Mottaghy, Gerhard Müller-Newen, Ulrich Simon
Journal: Advanced Healthcare Materials (2016)

As the size of nanoparticles (NPs) is in the range of biological molecules and subcellular structures, they provide new perspectives in biomedicine. This work presents studies concerning the cellular uptake and distribution of phosphine-stabilized cytotoxic 1.4 nm sized AuNPs and their probable degradation during this process. Therefore, ultrasmall phosphine-stabilized AuNPs are modified by linking a fluorophore covalently to the ligand shell. Monitoring the fluorescence on a cellular level by means of flow cytometry and confocal laser scanning microscopy allows determining the fate of the ligand shell during AuNP cell internalization, due to the fact that the fluorescence of a fluorophore bound near to the AuNP surface is quenched. Cell fractionation is conducted in order to quantify the AuNP content at the cell membrane, in the cytoplasm, and the cell nucleus. The incubation of cells with the fluorophore-modified AuNPs reveals a partial loss of the ligand shell upon AuNP cell interaction, evident by the emerging fluorescence signal. This loss is the precondition to unfold high AuNP cytotoxicity. Together with their significantly different biodistribution and enhanced circulation times compared to larger AuNPs, the findings demonstrate the high potential of ultrasmall AuNPs for drug development or therapy.
Cardiovascular Medications and Fractures
Authors: Cathleen S. Colón-Emeric, Richard Lee
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
A Unique Case of a Donor Cell Acute Myeloid Leukemia Reveals Complex Kinetics of Mutations and Evolution of the Disease
Authors: Sylvia Herold, Matthias Kuhn, Uwe Platzbecker, Stange Thoralf, Jörgen Radke, Caroline Heiderich, Lange Thoralf, Kerstin Gutsche, Johannes Schetelig, Stefani Parmentier, Brigitte Mohr, Markus Schaich, Hubert Serve, Christian H. Brandts, Martin Bornhäuser, Gerhard Ehninger, Christian Thiede
Journal: Blood (2012)
FRI0152 Relationship between Biological DMARDs Treatment and Complications after Surgical Treatment in Patients with Rheumatoid Arthritis
Authors: Y. Hirano, S. Hirabara, M. Isono, N. Ishiguro, T. Kojima
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Biological DMARDs (bDMARDs) have changed prognosis of rheumatoid arthritis (RA) dramatically and it is possible to reduce RA synovitis and to inhibit progression of joint destruction using bDMARDs. However, surgical treatment such as arthroplasty is still the important procedure in especially long-standing established RA patients. Information about safety and specific adverse events in surgical treatment under bDMARD treatment is lacking. <h3>Objectives</h3> This retrospective study investigated difference of complications between surgical treatment under bDMARDs treatment and that under conventional synthetic DMARDs (csDMARDs) treatment in RA patients. <h3>Methods</h3> 122 surgical operations for RA patients except operation to treat infectious conditions in our institute from 2010 to 2015 were included. 45 operations were performed under bDMARDs treatment (BG) and 77 operations were performed under csDMARDs treatment (nonBG). Patients9 characteristics, usage of dDMARDs, surgical site infection (SSI) and delayed wound healing (DWH) were compared between two groups. Time courses of hemoglobin (Hb), total protein, DAS28-CRP, SDAI and mHAQ after surgical operations were also compared between two groups. <h3>Results</h3> Mean age in BG was significantly younger than that in nonBG (60.1 years old vs. 66.9 years old). MTX usage in BG was significantry higher than that in nonBG (82.2% vs. 64.9%). 48 total knee arthroplasties, 14 total hip arthroplasties, 17 operation in hand and wrist, 29 operations in foot and ankle and 14 others were included. Used bDMARDs were etanercept in 24 cases, infliximab in 7 cases, abatacept in 6 case, adalimumab in 4 cases, tocilizumab in 3 cases and golimumab in 2 cases. Mean duration between stopping bDMARDs and surgical operation was 20.5 days. There was no significant difference in occurrences of SSI cases between two groups (BG: 0.0%, nonBG: 1.3%). There was no significant difference in occurrences of DWH between two groups (BG: 4.4%, nonBG: 11.7%). SDAI and mHAQ at 1–2 months after operation in nonBG were better than that in BG. mHAQ and recovery of Hb in nonBG were also better than that in BG. A SSI occurred in operation of ankle (1/29, 3.4%). DWH were frequently observed in foot and ankle operations (6 cases, 20.7%) and hand and wrist operations (3 cases, 17.6%) (Fig1). <h3>Conclusions</h3> There were no significant differences in SSI and DWH between BG and nonBG. mHAQ and Hb recovery after surgical operations in BG were slightly inferior to that in nonBG. This may be due to RA flare after operation in BG or differences of characteristics of patients. It was suggested that surgical region influences the occurrences of SSI and DWH and more complications were observed in foot and ankle operations. <h3>Disclosure of Interest</h3> None declared
The Relevance of the Inhibitory Receptor FcγIIB for the Regulation of Anti-Factor VIII Antibody Responses in Murine Models.
Authors: Christina Hausl, Pauline M. van Helden, Rafi U. Ahmad, Eva M. Muchitsch, Hans Peter Schwarz, Hartmut Ehrlich, Jan Voorberg, Birgit M. Reipert
Journal: Blood (2007)
Reduced Expression Level of SHP1 Gives An Additive Survival Advantage to the Ph+ Cells of Chronic Myeloid Leukemia (CML) Patients and Provides a Novel Pretreatment Predictor of Major Molecular Response Achievement in CML Patients.
Authors: Nicola Esposito, Concetta Quintarelli, Irene Colavita, Barbara Izzo, Anna Lucia Peluso, Margherita Ruoppolo, Luigi Del Vecchio, Domenico Russo, Susan Branford, Ilaria Iacobucci, Mark Thornquist, Matt Barnett, Junia Melo, Giuseppe Saglio, Jerald Radich, Lin Peter, Giovanni Martinelli, Thea Kalebic, Timothy Hughes, Fabrizio Pane
Journal: Blood (2009)
Potential contribution of the uterine microbiome in the development of endometrial cancer
Authors: Marina R. S. Walther-António, Jun Chen, Francesco Multinu, Alexis Hokenstad, Tammy J. Distad, E. Heidi Cheek, Gary L. Keeney, Douglas J. Creedon, Heidi Nelson, Andrea Mariani, Nicholas Chia
Journal: Genome Medicine (2016)

Endometrial cancer studies have led to a number of well-defined but mechanistically unconnected genetic and environmental risk factors. One of the emerging modulators between environmental triggers and genetic expression is the microbiome. We set out to inquire about the composition of the uterine microbiome and its putative role in endometrial cancer.We undertook a study of the microbiome in samples taken from different locations along the female reproductive tract in patients with endometrial cancer (n = 17), patients with endometrial hyperplasia (endometrial cancer precursor, n = 4), and patients afflicted with benign uterine conditions (n = 10). Vaginal, cervical, Fallopian, ovarian, peritoneal, and urine samples were collected aseptically both in the operating room and the pathology laboratory. DNA extraction was followed by amplification and high-throughput next generation sequencing (MiSeq) of the 16S rDNA V3-V5 region to identify the microbiota present. Microbiota data were summarized using both α-diversity to reflect species richness and evenness within bacterial populations and β-diversity to reflect the shared diversity between bacterial populations. Statistical significance was determined through the use of multiple testing, including the generalized mixed-effects model.The microbiome sequencing (16S rDNA V3-V5 region) revealed that the microbiomes of all organs (vagina, cervix, Fallopian tubes, and ovaries) are significantly correlated (p < 0.001) and that there is a structural microbiome shift in the cancer and hyperplasia cases, distinguishable from the benign cases (p = 0.01). Several taxa were found to be significantly enriched in samples belonging to the endometrial cancer cohort: Firmicutes (Anaerostipes, ph2, Dialister, Peptoniphilus, 1-68, Ruminococcus, and Anaerotruncus), Spirochaetes (Treponema), Actinobacteria (Atopobium), Bacteroidetes (Bacteroides and Porphyromonas), and Proteobacteria (Arthrospira). Of particular relevance, the simultaneous presence of Atopobium vaginae and an uncultured representative of the Porphyromonas sp. (99 % match to P. somerae) were found to be associated with disease status, especially if combined with a high vaginal pH (>4.5).Our results suggest that the detection of A. vaginae and the identified Porphyromonas sp. in the gynecologic tract combined with a high vaginal pH is statistically associated with the presence of endometrial cancer. Given the documented association of the identified microorganisms with other pathologies, these findings raise the possibility of a microbiome role in the manifestation, etiology, or progression of endometrial cancer that should be further investigated.